-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FFa6EQg0BJ3HiYHO7OMmch64VdKVyv7OvwlQ74qy7VEfAUYCJGz8sDWIqcPMScsc 1rDGdYDTdu3glbMfqEZI6w== 0000898432-03-000885.txt : 20030905 0000898432-03-000885.hdr.sgml : 20030905 20030905201835 ACCESSION NUMBER: 0000898432-03-000885 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030903 FILED AS OF DATE: 20030905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF INC/IL CENTRAL INDEX KEY: 0001056807 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19651 FILM NUMBER: 03884835 BUSINESS ADDRESS: STREET 1: 227 WEST MONROE STE STREET 2: STE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 3122637777 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENAERA CORP CENTRAL INDEX KEY: 0000880431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133445668 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5110 CAMPUS DR CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: 6109415231 MAIL ADDRESS: STREET 1: 5110 CAMPUS DRIVE CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 FORMER COMPANY: FORMER CONFORMED NAME: MAGAININ PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19651 FILM NUMBER: 03884838 BUSINESS ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 BUSINESS PHONE: 415-288-23 MAIL ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF INVESTMENTS LLC CENTRAL INDEX KEY: 0001132245 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19651 FILM NUMBER: 03884836 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST. 39TH FL CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3127392123 MAIL ADDRESS: STREET 1: C/O GROSVENOR CAPITAL MANAGEMENT LP STREET 2: 227 W. MONROE ST. #4800 CITY: CHICAGO STATE: IL ZIP: 60606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND II LP CENTRAL INDEX KEY: 0001102444 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19651 FILM NUMBER: 03884837 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST STREET 2: 39TH FL. CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3122637777 MAIL ADDRESS: STREET 1: C/O GROSVENOR CAPITAL MANAGEMENT STREET 2: 227 W. MONROE ST #4800 CITY: CHICAGO STATE: IL ZIP: 60606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BVF PARTNERS L P/IL CENTRAL INDEX KEY: 0001055947 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19651 FILM NUMBER: 03884839 BUSINESS ADDRESS: STREET 1: ONE SANSOME ST STREET 2: 39TH FL CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 3122637777 MAIL ADDRESS: STREET 1: 227 W MONROE STREET 2: SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 4 1 biotechnology_form4ex.xml X0201 4 2003-09-03 1 0000880431 GENAERA CORP GENR 0001055947 BVF PARTNERS L P/IL 227 WEST MONROE STREET SUITE 4800 CHICAGO IL 60606 0 0 1 0 0000918923 BIOTECHNOLOGY VALUE FUND L P 227 WEST MONROE STREET SUITE 4800 CHICAGO IL 60606 0 0 0 1 See Footnote (1) 0001102444 BIOTECHNOLOGY VALUE FUND II LP ONE SANSOME STREET 39TH FLOOR SAN FRANCISCO CA 94104 0 0 0 1 See Footnote (1) 0001132245 BVF INVESTMENTS LLC ONE SANSOME STREET 39TH FLOOR SAN FRANCISCO CA 94104 0 0 0 1 See Footnote (1) 0001056807 BVF INC/IL 227 WEST MONROE STREET SUITE 4800 CHICAGO IL 60606 0 0 1 0 Common Stock 2003-09-03 4 S 0 177000 4.81 D 1083000 I See Footnotes Common Stock 2003-09-03 4 S 0 112000 4.81 D 686000 I See Footnotes Common Stock 2003-09-03 4 S 0 271000 4.81 D 1668000 I See Footnotes Common Stock 2003-08-28 4 C 0 450000 0 A 1260000 I See Footnotes Common Stock 2003-08-28 4 C 0 285000 0 A 798000 I See Footnotes Common Stock 2003-08-28 4 C 0 693000 0 A 1938500 I See Footnotes Series C-1 Preferred Stock 2003-08-28 4 C 0 450000 0 D 2004-11-23 1998-08-08 Common Stock 450000 0 I See Footnotes Series C-1 Preferred Stock 2003-08-28 4 C 0 285000 0 D 2004-11-23 1998-08-08 Common Stock 285000 0 I See Footnotes Series C-1 Preferred Stock 2003-08-28 4 C 0 693000 0 D 2004-11-23 1998-08-08 Common Stock 693000 0 I See Footnotes The shares reported in this response are indirectly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner ("GP"), BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the GP of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments L.L.C., a Delaware limited liability company ("Investments"). Following the transactions reported in Table I, Item 5, Partners and BVF Inc. indirectly beneficially own in the aggregate 3,437,000 shares of common stock of Genaera Corp. Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in the shares of common stock reported in Table I as being beneficially owned by Investments. Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing. Shares are directly beneficially owned by BVF, L.P. Shares are directly beneficially owned by BVF2, L.P. Shares are directly beneficially owned by Investments. The reporting persons converted shares of Series C-1 Preferred Stock in the amounts shown in Table I, Item 4, at no cost. The conversion of Series C-1 Preferred Stock into Common Stock was a one-for-one conversion. Each share of Series C-1 Preferred Stock is convertible into Common Stock at the option of the holder, on or after November 23, 2004, subject to earlier conversion in certain circumstances as set forth in the respective Certificates of Designation of the Rights, Preferences and Privileges for the Series C-1 Preferred Stock. During August 2003, earlier conversion of the Series C-1 Preferred Stock was triggered. Information created to satisfy SEC Form 4 input requirements. There is no expiration date. BVF Partners L.P., By: BVF, Inc., its GP, By: /s/ Mark N. Lampert 2003-09-05 BIOTECHNOLOGY VALUE FUND, L.P., By: BVF Partners, L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert 2003-09-05 BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert 2003-09-05 BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its Manager, By: BVF Inc., By: /s/ Mark N. Lampert 2003-09-05 BVF INC., By: /s/ Mark N. Lampert 2003-09-05 /s/ Mark N. Lampert 2003-09-05 -----END PRIVACY-ENHANCED MESSAGE-----